It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, comorbidities, smoking, regular or remote working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family interactions. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the anti-spike antibody response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 IRCCS Humanitas Research Hospital, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
2 Mario Negri” - IRCCS, Istituto Di Ricerche Farmacologiche, Milan, Italy (GRID:grid.4527.4) (ISNI:0000000106678902)
3 Humanitas University, Department of Biomedical Sciences, Milan, Italy (GRID:grid.452490.e)
4 Humanitas Gavazzeni and Castelli, Bergamo, Italy (GRID:grid.477189.4) (ISNI:0000 0004 1759 6891)
5 IRCCS Humanitas Research Hospital, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807); Humanitas University, Department of Biomedical Sciences, Milan, Italy (GRID:grid.452490.e); The William Harvey Research Institute, Queen Mary University of London, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
6 IRCCS Humanitas Research Hospital, Milan, Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807); Humanitas University, Department of Biomedical Sciences, Milan, Italy (GRID:grid.452490.e)




